Insider Selling: WAVE Life Sciences (NASDAQ:WVE) CEO Sells $140,956.00 in Stock

WAVE Life Sciences Ltd. (NASDAQ:WVE) CEO Paul Bolno sold 10,480 shares of WAVE Life Sciences stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $140,956.00. Following the sale, the chief executive officer directly owned 275,520 shares in the company, valued at $3,705,744. The trade was a 3.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

WAVE Life Sciences Price Performance

NASDAQ:WVE opened at $12.68 on Friday. The firm’s 50 day simple moving average is $15.20 and its 200 day simple moving average is $10.43. WAVE Life Sciences Ltd. has a one year low of $5.28 and a one year high of $21.73. The company has a market cap of $2.12 billion, a PE ratio of -16.91 and a beta of -1.78.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in WVE. CWM LLC increased its holdings in shares of WAVE Life Sciences by 6,729.0% during the fourth quarter. CWM LLC now owns 2,117 shares of the company’s stock valued at $36,000 after acquiring an additional 2,086 shares in the last quarter. Smartleaf Asset Management LLC grew its position in WAVE Life Sciences by 645.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after purchasing an additional 1,942 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in WAVE Life Sciences in the 4th quarter valued at $82,000. Mirae Asset Global Investments Co. Ltd. increased its stake in WAVE Life Sciences by 32.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,124 shares of the company’s stock valued at $138,000 after purchasing an additional 1,972 shares in the last quarter. Finally, Bessemer Group Inc. raised its holdings in WAVE Life Sciences by 1,156.3% during the third quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock worth $72,000 after buying an additional 9,135 shares during the last quarter. 89.73% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on WVE shares. B. Riley Financial increased their price objective on WAVE Life Sciences from $19.00 to $37.00 and gave the company a “buy” rating in a report on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Wednesday, January 21st. UBS Group set a $32.00 price objective on WAVE Life Sciences in a research report on Tuesday, December 16th. Wall Street Zen lowered WAVE Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Finally, Royal Bank Of Canada raised shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $9.00 to $27.00 in a research report on Monday, December 8th. Fourteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, WAVE Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.56.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.